Posted inNews and Updates
Iza-bren Advances to Phase 3 Trials for Lung Cancer
Iza-bren advances to Phase 3 trials for EGFR-mutated NSCLC. Discover how the 2.5 mg/kg dose aims to improve lung cancer outcomes in this new report.
Posted inNews and Updates
Tam-Peli Hits Phase III Milestone in Lung Cancer Trial
Tam-Peli reaches a major Phase III milestone for relapsed small-cell lung cancer, potentially offering a new survival-extending option for patients.
Posted inNews and Updates
New Lung Cancer Drug Extends Survival in Relapsed SCLC
Clinical trial results show risvutatug rezetecan significantly boosts overall survival in patients with relapsed small-cell lung cancer. Learn more here.
Posted inNews and Updates
Merck and Gilead Trodelvy Trial: New Insights on Lung Cancer
Trodelvy’s lung cancer trial failed globally but showed promise in China. Explore the implications for this antibody-drug conjugate in modern oncology.
Posted inNews and Updates
Africa Boosts Ebola Vaccine Research and Clinical Capacity
Africa is expanding its clinical trial infrastructure to accelerate Ebola vaccine development, boosting regional research, safety, and global health security.
Posted inNews and Updates
AstraZeneca’s Etcamah Fails Key Breast Cancer Trial
AstraZeneca’s oral SERD, etcamah, misses primary endpoints in a first-line breast cancer trial, marking another hurdle for the class of targeted therapies.
Posted inNews and Updates
SeaStar Medical Gears Up for Critical Adult Clinical Trial
SeaStar Medical eyes critical growth as it prepares to launch a pivotal clinical trial for its inflammatory-targeting therapy in adult patients.
Posted inNews and Updates
Breast Cancer Drug Fails Trial After Regulatory Approval
A key breast cancer treatment faces scrutiny after failing a confirmatory clinical trial shortly after receiving regulatory approval. Read the latest updates.
Posted inNews and Updates
New FDA Guidance: Navigating Psychedelic Trial Design
The FDA has released its 2026 guidance for psychedelic drug trials. Learn how new standards for blinding and patient safety will shape future research.
Posted inNews and Updates
The $77 Billion Race to Revolutionize Clinical Trials
Explore how a $77 billion investment in AI is reshaping clinical trials, reducing drug development costs, and accelerating the delivery of new treatments.